Genotropin Stungulyfsstofn og leysir, lausn 5 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

genotropin stungulyfsstofn og leysir, lausn 5 mg

pfizer aps - somatropinum inn - stungulyfsstofn og leysir, lausn - 5 mg

Bluevac BTV (previously known as Bluevac BTV8) Evrópusambandið - íslenska - EMA (European Medicines Agency)

bluevac btv (previously known as bluevac btv8)

cz veterinaria s.a. - bluetongue virus vaccine serotypes 1 or 4 or 8 [inactivated] - Ónæmisfræðilegar upplýsingar - sheep; cattle - sheepactive bólusetningar gegn bluetongue veira serotype 8 til að koma í veg fyrir viraemia og til að draga úr klínískum merki. upphaf ónæmis: 20 dagar eftir annan skammt. lengd ónæmis: 1 ár eftir annan skammt. cattleactive bólusetningar gegn bluetongue veira serotype 8 til að koma í veg fyrir viraemia. upphaf ónæmis: 31 dagar eftir annan skammt. lengd ónæmis: 1 ár eftir annan skammt.

Ibutrix Mixtúra, dreifa 20 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

ibutrix mixtúra, dreifa 20 mg/ml

williams & halls ehf. - ibuprofenum inn - mixtúra, dreifa - 20 mg/ml

Kimmtrak Evrópusambandið - íslenska - EMA (European Medicines Agency)

kimmtrak

immunocore ireland limited - tebentafusp - uveal neoplasms - Æxlishemjandi lyf - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

Tecvayli Evrópusambandið - íslenska - EMA (European Medicines Agency)

tecvayli

janssen-cilag international n.v. - teclistamab - mergæxli - Æxlishemjandi lyf - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Nicorette Invisi Forðaplástur 10 mg/16 klst. Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

nicorette invisi forðaplástur 10 mg/16 klst.

mcneil denmark aps - nicotinum - forðaplástur - 10 mg/16 klst.

Nicorette Invisi Forðaplástur 15 mg/16 klst. Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

nicorette invisi forðaplástur 15 mg/16 klst.

mcneil denmark aps - nicotinum - forðaplástur - 15 mg/16 klst.

Nicorette Invisi Forðaplástur 25 mg/16 klst. Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

nicorette invisi forðaplástur 25 mg/16 klst.

mcneil denmark aps - nicotinum - forðaplástur - 25 mg/16 klst.

Columvi Evrópusambandið - íslenska - EMA (European Medicines Agency)

columvi

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - Æxlishemjandi lyf - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.

Jakavi Evrópusambandið - íslenska - EMA (European Medicines Agency)

jakavi

novartis europharm limited - ruxolitinib (sem fosfat) - myeloproliferative disorders; polycythemia vera; graft vs host disease - Æxlishemjandi lyf - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (Úsbekistan)ráðlagt er ætlað fyrir meðferð fullorðinn sjúklinga með polycythaemia vera sem eru ónæmir fyrir eða þola hýdroxýúrea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.